Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $5.4 million.

  • Intellia Therapeutics' Gains from Investment Securities fell 3.77% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $5.4 million for FY2024, which is 0.85% down from last year.
  • As of FY2024, Intellia Therapeutics' Gains from Investment Securities stood at $5.4 million, which was down 0.85% from $5.5 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Gains from Investment Securities high stood at $7.0 million for FY2020, and its period low was $5.4 million during FY2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $5.5 million (2023), whereas its average is $5.4 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 30.03% in 2020, then declined by 13.22% in 2022.
  • Intellia Therapeutics' Gains from Investment Securities (Yearly) stood at $7.0 million in 2020, then dropped by 9.64% to $6.3 million in 2021, then decreased by 13.22% to $5.5 million in 2022, then declined by 0.23% to $5.5 million in 2023, then declined by 0.85% to $5.4 million in 2024.